New long acting insulin

There have been several new long-acting insulin products approved in recent years. Here are a few examples:

  1. LixiLan (insulin glargine and lixisenatide): Approved in 2016, LixiLan is a fixed-ratio combination of insulin glargine (a long-acting insulin) and lixisenatide (a glucagon-like peptide-1 receptor agonist). It is used to improve glycemic control in adults with type 2 diabetes.
  2. Basaglar (insulin glargine): Approved in 2015, Basaglar is a long-acting insulin that is similar to Lantus (insulin glargine). It is used to improve glycemic control in adults with type 1 and type 2 diabetes.
  3. Tresiba (insulin degludec): Approved in 2014, Tresiba is a long-acting insulin that is used to improve glycemic control in adults with type 1 and type 2 diabetes. It has a duration of action of up to 42 hours.
  4. Ryzodeg (insulin degludec and insulin aspart): Approved in 2012, Ryzodeg is a fixed-ratio combination of insulin degludec (a long-acting insulin) and insulin aspart (a rapid-acting insulin). It is used to improve glycemic control in adults with type 1 and type 2 diabetes.
  5. Xultophy (insulin degludec and liraglutide): Approved in 2014, Xultophy is a fixed-ratio combination of insulin degludec (a long-acting insulin) and liraglutide (a glucagon-like peptide-1 receptor agonist). It is used to improve glycemic control in adults with type 2 diabetes.

These new long-acting insulins offer improved glycemic control, reduced risk of hypoglycemia, and more flexible dosing regimens compared to older insulin products. However, it's important to note that each patient's response to insulin therapy is unique, and the choice of insulin product should be made in consultation with a healthcare provider.